269 related articles for article (PubMed ID: 30251947)
1. PREFERENCES OF PATIENTS WITH MULTIPLE SCLEROSIS FOR ATTRIBUTES OF INJECTABLE MULTIPLE SCLEROSIS TREATMENTS IN THE UNITED KINGDOM AND FRANCE.
Poulos C; Kinter E; van Beek J; Christensen K; Posner J
Int J Technol Assess Health Care; 2018 Jan; 34(4):425-433. PubMed ID: 30251947
[TBL] [Abstract][Full Text] [Related]
2. Patient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Reder AT
Patient; 2016 Apr; 9(2):171-80. PubMed ID: 26259849
[TBL] [Abstract][Full Text] [Related]
3. A discrete-choice experiment to determine patient preferences for injectable multiple sclerosis treatments in Germany.
Poulos C; Kinter E; Yang JC; Bridges JF; Posner J; Gleißner E; Mühlbacher A; Kieseier B
Ther Adv Neurol Disord; 2016 Mar; 9(2):95-104. PubMed ID: 27006697
[TBL] [Abstract][Full Text] [Related]
4. A discrete choice experiment to determine UK patient preference for attributes of disease modifying treatments in Multiple Sclerosis.
Bottomley C; Lloyd A; Bennett G; Adlard N
J Med Econ; 2017 Aug; 20(8):863-870. PubMed ID: 28562125
[TBL] [Abstract][Full Text] [Related]
5. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
[TBL] [Abstract][Full Text] [Related]
6. A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.
Hauber AB; Nguyen H; Posner J; Kalsekar I; Ruggles J
Curr Med Res Opin; 2016; 32(2):251-62. PubMed ID: 26549576
[TBL] [Abstract][Full Text] [Related]
7. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
8. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment preferences among health care providers in the United States in selecting disease modifying therapies for patients with multiple sclerosis: a discrete choice experiment.
Bandari D; Adamson M; Bowman M; Gutierrez A; Athavale A; Oak B; Hadker N; Branco F; Geremakis C; Lewin JB; Shankar SL
J Med Econ; 2023; 26(1):1507-1518. PubMed ID: 37934412
[TBL] [Abstract][Full Text] [Related]
10. Factors Associated with Patient Preferences for Disease-Modifying Therapies in Multiple Sclerosis.
Hincapie AL; Penm J; Burns CF
J Manag Care Spec Pharm; 2017 Aug; 23(8):822-830. PubMed ID: 28737987
[TBL] [Abstract][Full Text] [Related]
11. Patient preferences for osteoarthritis pain and chronic low back pain treatments in the United States: a discrete-choice experiment.
Turk D; Boeri M; Abraham L; Atkinson J; Bushmakin AG; Cappelleri JC; Hauber B; Klein K; Russo L; Viktrup L; Walsh D
Osteoarthritis Cartilage; 2020 Sep; 28(9):1202-1213. PubMed ID: 32652238
[TBL] [Abstract][Full Text] [Related]
12. Physicians' preferences for bone metastases treatments in France, Germany and the United Kingdom.
Qian Y; Arellano J; Gatta F; Hechmati G; Hauber AB; Mohamed AF; Bahl A; von Moos R; Body JJ
BMC Health Serv Res; 2018 Jul; 18(1):518. PubMed ID: 29970078
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Reproductive Issues on Preferences of Women with Relapsing Multiple Sclerosis for Disease-Modifying Treatments.
Webb EJD; Meads D; Eskytė I; Ford HL; Bekker HL; Chataway J; Pepper G; Marti J; Okan Y; Pavitt SH; Schmierer K; Manzano A
Patient; 2020 Oct; 13(5):583-597. PubMed ID: 32588337
[TBL] [Abstract][Full Text] [Related]
14. Patients' preferences and willingness-to-pay for disease-modifying therapies.
Frost N; Freeman J; Brixner D; Mort J; Clem J; Ngorsuraches S
Mult Scler Relat Disord; 2019 Oct; 35():55-60. PubMed ID: 31323483
[TBL] [Abstract][Full Text] [Related]
15. Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
González JM; Doan J; Gebben DJ; Boeri M; Fishman M
Pharmacoeconomics; 2018 Aug; 36(8):973-986. PubMed ID: 29869777
[TBL] [Abstract][Full Text] [Related]
16. Improving Patient-Centered Care by Assessing Patient Preferences for Multiple Sclerosis Disease-Modifying Agents: A Stated-Choice Experiment.
Carlin CS; Higuera L; Anderson S
Perm J; 2017; 21():16-102. PubMed ID: 28406788
[TBL] [Abstract][Full Text] [Related]
17. Preferences for Multiple Sclerosis Treatments: Using a Discrete-Choice Experiment to Examine Differences Across Subgroups of US Patients.
Mansfield C; Thomas N; Gebben D; Lucas M; Hauber AB
Int J MS Care; 2017; 19(4):172-183. PubMed ID: 28835741
[TBL] [Abstract][Full Text] [Related]
18. Patient and parent preferences for immunoglobulin treatments: a conjoint analysis.
Mohamed AF; Kilambi V; Luo MP; Iyer RG; Li-McLeod JM
J Med Econ; 2012; 15(6):1183-91. PubMed ID: 22846048
[TBL] [Abstract][Full Text] [Related]
19. Patients' Preferences for the Treatment of Metastatic Castrate-resistant Prostate Cancer: A Discrete Choice Experiment.
Eliasson L; de Freitas HM; Dearden L; Calimlim B; Lloyd AJ
Clin Ther; 2017 Apr; 39(4):723-737. PubMed ID: 28366592
[TBL] [Abstract][Full Text] [Related]
20. Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey.
Mansfield C; Sikirica MV; Pugh A; Poulos CM; Unmuessig V; Morano R; Martin AA
Diabetes Ther; 2017 Dec; 8(6):1365-1378. PubMed ID: 29101681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
